BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
About the study
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
Documented diagnosis of PH1, per physician's determination
EXCLUSION CRITERIA
Exclusion Criteria:
Currently enrolled in a clinical trial for any investigational agent
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Primary Hyperoxaluria Type 1
Participants needed
200
Est. Completion Date
Sep 30, 2028
Treatment type
Observational
Sponsor
Alnylam Pharmaceuticals
ClinicalTrials.gov identifier
NCT04982393
Study number
ALN-GO1-007
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?